Health
Moderna and Merck Cancer Vaccine Success
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in melanoma patients by 42% compared to standard treatment, according to detailed data from a clinical trial.
Coverage timeline — 1 article
STAT News
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
2026-10-22 19:03 UTC